Skip to main content
Premium Trial:

Request an Annual Quote

UK Coronavirus Genomics Consortium Gets £12.2M Additional Funding to Expand Sequencing Efforts

NEW YORK — The COVID-19 Genomics UK (COG-UK) Consortium on Saturday said that it has been awarded £12.2 million ($16.1 million) in new funding to expand its SARS-CoV-2 surveillance efforts.

COG-UK was established in March with £20 million from the UK's National Health Service (NHS) and other public health and research organizations to perform sequencing-based studies of SARS-CoV-2 transmission and evolution. To date, it has generated and made publicly available more than 100,000 SARS-CoV-2 genomes.

With the new funding, COG-UK aims to increase its sequencing capacity and reduce the turnaround time from patient sample to genome sequence as SARS-CoV-2 case numbers rise in the UK.

"The pattern of accumulation of mutations in the genomes enables us to determine the relatedness of virus samples and define viral lineages in order to understand whether local outbreaks are caused by transmission of single or multiple viral lineages," COG-UK Director Sharon Peacock said in a statement. "Analysis of viral genome sequences also allows us to monitor the evolution of SARS-CoV-2 and assess whether specific mutations influence transmission, disease severity, or the impact of interventions such as vaccines."

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.